BAAM
SNDX icon

Baker Avenue Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Baker Avenue Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31
Closed -$450 – 1310
2023
Q3 		$450 Sell
31
-11
-26% -$208 ﹤0.01% 1496
2023
Q2 		$879 Sell
42
-21
-33% -$437 ﹤0.01% 1216
2023
Q1 		$1.33K Hold
63
– – ﹤0.01% 1092
2022
Q4 		$1.6K Buy
+63
New +$1.47K ﹤0.01% 978

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Baker Avenue Asset Management's SNDX Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 31 shares — an estimated $450 sold.

Baker Avenue Asset Management first reported a position in SNDX in Q4 2022 and held it in 4 quarters. The position peaked at $1.6K in Q4 2022. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 31 Syndax Pharmaceuticals shares in Q4 2023, an estimated $450.
  • Baker Avenue Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Syndax Pharmaceuticals position peaked at $1.6K in Q4 2022.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.